Schonfeld Strategic Advisors LLC Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Schonfeld Strategic Advisors LLC decreased its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 19.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 49,410 shares of the biotechnology company's stock after selling 11,952 shares during the quarter. Schonfeld Strategic Advisors LLC owned about 0.05% of Sarepta Therapeutics worth $6,008,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. Charles Schwab Investment Management Inc. increased its position in shares of Sarepta Therapeutics by 2.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company's stock valued at $75,842,000 after acquiring an additional 12,000 shares during the period. Proficio Capital Partners LLC acquired a new position in shares of Sarepta Therapeutics in the fourth quarter valued at about $3,829,000. Nordea Investment Management AB raised its stake in shares of Sarepta Therapeutics by 19.1% in the fourth quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company's stock worth $8,228,000 after purchasing an additional 10,815 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Sarepta Therapeutics by 16,717.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company's stock worth $10,602,000 after purchasing an additional 84,926 shares during the period. Finally, Van ECK Associates Corp boosted its position in Sarepta Therapeutics by 24.4% in the fourth quarter. Van ECK Associates Corp now owns 84,834 shares of the biotechnology company's stock valued at $10,315,000 after buying an additional 16,658 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Insiders Place Their Bets

In related news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company's stock, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 7.70% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have commented on SRPT shares. Scotiabank decreased their price objective on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research note on Thursday, March 20th. Royal Bank of Canada lowered shares of Sarepta Therapeutics from an "outperform" rating to a "sector perform" rating and lowered their price target for the company from $161.00 to $87.00 in a report on Monday, March 31st. Deutsche Bank Aktiengesellschaft cut their price target on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research report on Wednesday, March 19th. Wells Fargo & Company initiated coverage on Sarepta Therapeutics in a research note on Friday, April 11th. They issued an "overweight" rating and a $115.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $163.00 price target on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. Six research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $158.70.

Sarepta Therapeutics Stock Performance

NASDAQ:SRPT opened at $62.78 on Friday. Sarepta Therapeutics, Inc. has a twelve month low of $48.01 and a twelve month high of $173.25. The company has a market cap of $6.17 billion, a P/E ratio of 50.22 and a beta of 0.93. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company's 50-day moving average price is $73.73 and its 200-day moving average price is $104.12.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.